Risk of breast cancer with HRT depends on therapy type and durationBMJ 2022; 376 doi: https://doi.org/10.1136/bmj.o485 (Published 08 March 2022) Cite this as: BMJ 2022;376:o485
- Helen Saul, editor in chief1,
- Deniz Gursul, research dissemination officer1,
- Samantha Cassidy, science writer1,
- Yana Vinogradova, senior research fellow2
- Correspondence to H Saul
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:m3873.
To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/risk-of-breast-cancer-with-hrt-depends-therapy-type-and-duration/
Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none.
Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests
All authors contributed to the development and review of this summary, as part of the wider NIHR Alerts editorial team.
More summaries of NIHR research are available at https://evidence.nihr.ac.uk/alerts/
Disclaimer: NIHR Alerts are owned by the Department of Health and Social Care and are made available to The BMJ under licence. NIHR Alerts report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Alerts.
Permission to reuse these articles should be directed to